Published in Bone Marrow Transplant on March 11, 2020
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol (2014) 4.37
MYC dysregulation in the progression of multiple myeloma. Leukemia (2019) 1.38
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood (2014) 1.12
Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol (2014) 0.94
New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J (2016) 0.87
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant (2015) 0.86
Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Am J Hematol (2017) 0.81
A practical review on carfilzomib in multiple myeloma. Eur J Haematol (2016) 0.79
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J (2015) 0.79
Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol (2015) 0.76
Herbs for hematology. Leuk Lymphoma (2010) 0.75
Emerging role of CEBP-α mutations in acute myeloid leukemia. Eur J Haematol (2015) 0.75
Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia (2015) 0.75
Spinal Metastases of Extramammary Paget Disease with Radiologic-Pathologic Correlation. J Radiol Case Rep (2016) 0.75
Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica (2016) 0.75
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood (2016) 0.75
Blind men and an elephant. Blood (2015) 0.75
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant (2016) 0.75
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J (2016) 0.75
Oyster-shaped hyperkeratotic plaques on the penis. Dermatol Pract Concept (2015) 0.75
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol (2017) 0.75
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol (2017) 0.75
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J (2020) 0.75
Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol (2017) 0.75
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. Am J Hematol (2017) 0.75
Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology (2015) 0.75
Frequency of cutis laxa-like clinical features and elastolysis in scleromyxedema: a retrospective clinicopathologic study of 19 patients with scleromyxedema. J Cutan Pathol (2016) 0.75
Natural history of amyloidosis isolated to fat and bone marrow aspirate. Br J Haematol (2016) 0.75
Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica (2017) 0.75
Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. Am J Hematol (2017) 0.75
Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). Blood Cancer J (2022) 0.75
Exfoliative erythroderma after tumor necrosis factor-α inhibitor therapy. Int J Dermatol (2016) 0.75
Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. J Oncol Pharm Pract (2021) 0.75
Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. Br J Haematol (2017) 0.75
Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases. Eur Respir J (2017) 0.75
Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. Leuk Lymphoma (2017) 0.75
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy(). Leuk Lymphoma (2017) 0.75
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat (2017) 0.75
Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis (2016) 0.75
The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. Br J Haematol (2017) 0.75
Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol (2017) 0.75
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia (2017) 0.75
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J (2017) 0.75
Impact of MYD88 Mutation Status in Waldenström Macroglobulinemia. Am J Hematol (2017) 0.75
Checking in: T cells against multiple myeloma. Blood (2017) 0.75
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Am J Hematol (2017) 0.75
Management of macroglobulinaemia. Br J Haematol (2017) 0.75
Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol (2017) 0.75
Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. Eur J Haematol (2017) 0.75
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid (2021) 0.75
Immune-based therapies in the management of multiple myeloma. Blood Cancer J (2020) 0.75
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Br J Haematol (2017) 0.75
Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial. Leukemia (2017) 0.75
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary CNS Lymphoma: A Mayo Clinic Experience. Biol Blood Marrow Transplant (2020) 0.75
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J (2017) 0.75